It’s all in our name: Volition means to have determination and a purpose
From penicillin to vaccines to genome editing, all the greatest scientiﬁc discoveries have something in common: the determination to transform lives on a global scale, no matter what hurdles block the path of progress.
That’s why we named ourselves Volition, to honor the central importance and absolute focus of that purpose and determination in revolutionizing the way disease is diagnosed and monitored.
We are determined to revolutionize the way disease is diagnosed and monitored. Here are the values that drive us every day.
We believe in ourselves
We believe wholeheartedly in the power of our technology, our products, and our people. Nucleosomics™ technology has the potential to play an important role in the ﬁght to save lives and improve outcomes worldwide. This belief and passion are what drive and sustain us and everyone who joins us.
We act with humility
We are inspired every day by the potential of what we do and what we can achieve together. Our horizon is continuously expanding beyond cancer to a whole range of life-altering diseases, beyond humans to animals, to ﬁnd and address a host of unmet clinical needs, always with the patient at the forefront of our minds.
We are in this together, for everyone
The science of what we do is detailed and complex, but Nu.Q® itself is not. A simple, routine blood test, like a blood sugar or cholesterol test, our goal is that Nu.Q® will be aﬀordable and available to all. And this is the essence of who we are. We are in this together, for everyone.
We dare to be different
What we do and the way we do it is completely unique. We dare to challenge the status quo to advance the science of epigenetics and improve outcomes for people and animals worldwide. We seek to change the world by allowing physicians to use the hidden information in chromosomes to detect disease earlier, monitor it more eﬀectively and help improve outcomes.
We strive to be the best
Our team are leading experts in epigenetics. For over a decade we have evolved and mastered our understanding of nucleosomes. We have developed and reﬁned our technology to be what we believe to be the best-in-class in the diagnostics industry. Everything we do, we do to the very best of our ability.
Volition was established in 2010. Our co-founding scientists, Jake Micallef and Mark Eccleston joined forces with our Group CEO, Cameron Reynolds, with the aim of transforming cancer diagnostics from expensive, invasive, and often unpleasant procedures to something as fast and accessible as cholesterol or pregnancy testing.
The company has grown from a single two-meter lab bench at the University of Namur in Belgium to a purpose-built 20,000 square feet lab in Gembloux, Belgium, an Innovation Lab in California, and offices in California, London, Singapore and Nevada.
In 2015 the company was listed on the New York Stock Exchange (VNRX). We now have a team of over 100 dedicated staff, spanning a wide range of disciplines; all united in our mission to improve outcomes for patients.